Insider Selling: ADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells 20,000 Shares of Stock

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director now owns 94,830 shares in the company, valued at $1,987,636.80. The trade was a 17.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

ADMA Biologics Price Performance

ADMA stock traded down $0.27 during mid-day trading on Thursday, hitting $21.60. The company had a trading volume of 3,627,666 shares, compared to its average volume of 3,665,243. The company has a market capitalization of $5.16 billion, a price-to-earnings ratio of 77.14 and a beta of 0.47. ADMA Biologics, Inc. has a 12-month low of $10.21 and a 12-month high of $25.67. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average price of $20.81 and a 200 day moving average price of $18.88.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. During the same quarter last year, the firm earned $0.08 earnings per share. The business's quarterly revenue was up 40.2% on a year-over-year basis. On average, research analysts anticipate that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on ADMA. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Finally, Raymond James boosted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, ADMA Biologics has an average rating of "Moderate Buy" and an average target price of $24.25.

Institutional Trading of ADMA Biologics

A number of large investors have recently made changes to their positions in ADMA. Nuveen LLC bought a new stake in shares of ADMA Biologics in the 1st quarter worth about $93,543,000. Allspring Global Investments Holdings LLC grew its holdings in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after purchasing an additional 2,613,482 shares during the last quarter. B Group Inc. bought a new position in ADMA Biologics during the 4th quarter valued at about $39,231,000. Driehaus Capital Management LLC grew its holdings in ADMA Biologics by 114.9% during the 1st quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company's stock valued at $58,460,000 after purchasing an additional 1,575,363 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock valued at $255,279,000 after purchasing an additional 1,570,649 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.